読み込み中
NASDAQHealthcareBiotechnology
最新データ
$7.30
+$0.02 · +0.27%
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
前日終値
$7.30
+$0.02 · +0.27%
日中の時刻はETです。市場データは遅延する場合があります。
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
日中レンジ
現在 $7.30
52週レンジ
現在 $7.30
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
88
大幅な割安
センチメント
73
強気
リスク
74
高リスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
日中レンジ
現在 $7.30
52週レンジ
現在 $7.30
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1310.7万 USD | 1009.4万 USD | 776.8万 USD | — | — |
| 売上原価 | 856.5万 USD | 776.5万 USD | 474.1万 USD | — | — |
| 粗利益 | 454.2万 USD | 232.9万 USD | 302.7万 USD | — | — |
| 研究開発 | 4448.6万 USD | 4044.8万 USD | 8665.5万 USD | 8187.6万 USD | 6883.8万 USD |
| 販売・一般管理 | 8575.9万 USD | 4010.1万 USD | 3475.2万 USD | 3021.5万 USD | 2347.4万 USD |
| 営業費用 | 1.3億 USD | 1.39億 USD | 1.21億 USD | 1.12億 USD | 9231.2万 USD |
| 受取利息 | 414.6万 USD | — | — | 187.3万 USD | 2.5万 USD |
| 支払利息 | 8.9万 USD | — | — | — | — |
| 減価償却費と償却費 | 192.5万 USD | 342.1万 USD | 429.1万 USD | 125.3万 USD | 5万 USD |
| 営業利益 | −1.26億 USD | −1.37億 USD | −1.18億 USD | −1.12億 USD | −9231.2万 USD |
| 純利益 | −1.24億 USD | −1.3億 USD | −1.17億 USD | −1.1億 USD | −9228.7万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2025年2月5日 | 1:100 | — | — |
株式分割 | 2024年6月10日 | 1:32 | — | — |
株式分割 | 2023年5月10日 | 4:25 | — | — |
株式分割 | 2022年5月17日 | 1:32 | — | — |
株式分割 | 2019年11月1日 | 1:10 | — | — |
株式分割 | 2018年11月28日 | 1:10 | — | — |
発効済み 2025年2月5日
1:100
発効済み 2024年6月10日
1:32
発効済み 2023年5月10日
4:25
発効済み 2022年5月17日
1:32
発効済み 2019年11月1日
1:10
発効済み 2018年11月28日
1:10
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI688.23万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM312.38万0.00%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF264.25万0.00%954億 USD0.05%$235+0.80%
Fidelity Enhanced Small Cap ETFFESM146.74万0.02%64.1億 USD0.28%$45.46+0.46%
Vanguard Russell 2000 ETFVTWO118.55万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC37.34万0.03%13.17億 USD0.60%$183+0.11%
Invesco RAFI US 1500 Small-Mid ETFPRFZ25.89万0.01%26.7億 USD0.36%$53.16+0.64%
Vanguard Russell 2000 Value ETFVTWV19.41万0.01%14億 USD0.06%$185.81-0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZVanguard Russell 2000 Value ETFVTWVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
